Blue print medicine stock8/2/2023 ![]() ![]() Analysts expect adjusted earnings to reach $-9.695 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was 1.0%. Blueprint Medicines Corp’s trailing 12-month revenue is $204.6 million with a -284.0% net profit margin. FibroGen Inc does not currently pay a dividend.Ĭurrently, Blueprint Medicines Corp does not have a price-earnings ratio. Analysts expect adjusted earnings to reach $-2.520 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was -40.5%. FibroGen Inc’s trailing 12-month revenue is $116.1 million with a -264.6% net profit margin. FibroGen Inc’s stock is NA in 2023, NA in the previous five trading days and up 77.68% in the past year.Ĭurrently, FibroGen Inc does not have a price-earnings ratio. Latest Biotechnology & Medical Research and FibroGen Inc, Blueprint Medicines Corp Stock NewsĪs of June 16, 2023, FibroGen Inc had a $1.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $103.7 million. It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.īlueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The Company?s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. Read on to learn how FibroGen Inc and Blueprint Medicines Corp compare based on key financial metrics to determine which better meets your investment needs.Ībout FibroGen Inc and Blueprint Medicines CorpįibroGen, Inc. If you’re on the fence about investing in FibroGen Inc or Blueprint Medicines Corp because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Sifting through countless of stocks in the Biotechnology & Medical Research industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |